MyAverix Finance MyAverix Finance

SHE · Healthcare

Staidson Beijing Biopharma (300204)

Biotechnology

Staidson Beijing Biopharma (300204) is listed on SHE in the Healthcare sector. Industry: Biotechnology. As of 2026-03-25, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-03-25

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for 300204

P/E ratio
18.00

Staidson Beijing Biopharma (300204) — FAQ

What is 300204's P/E ratio?

The price-to-earnings (P/E) ratio for Staidson Beijing Biopharma (300204) is 18.00 (data as of 2026-03-25).

Does Staidson Beijing Biopharma pay a dividend?

Dividend yield is not available in the current snapshot for Staidson Beijing Biopharma (300204). Check the MyAverix Finance app for the latest dividend data.

What sector is Staidson Beijing Biopharma in?

Staidson Beijing Biopharma (300204) is classified in the Healthcare sector (Biotechnology industry).

What exchange is 300204 listed on?

300204 is listed on SHE.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play